LGVN CIK: 1721484

Longeveron Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
35.4
FY22:
20.3
FY23:
5.85
FY24:
19.6
FY25:
5.45
(positive)
Change from FY21 to FY25
millions USD
FY21:
7.39
FY22:
7.13
FY23:
6.23
FY24:
5.93
FY25:
4.81
Total assets
Change from FY21 to FY25
millions USD
FY21:
42.8
FY22:
27.4
FY23:
12.1
FY24:
25.6
FY25:
10.3

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
2.71
FY22:
4.87
FY23:
3.89
FY24:
2.58
FY25:
4.09
(negative)
Change from FY21 to FY25
millions USD
FY21:
2.61
FY22:
2.04
FY23:
1.45
FY24:
1.09
FY25:
0.50
(positive)
Change from FY21 to FY25
millions USD
FY21:
37.5
FY22:
20.5
FY23:
6.74
FY24:
21.9
FY25:
5.68
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
42.8
FY22:
27.4
FY23:
12.1
FY24:
25.6
FY25:
10.3

All amounts in millions USD Data source:SEC EDGAR